Recent studies suggest that over 50% of prostate tumours may carry a chromosomal rearrangement of chromosome 21q221. The genes involved are the androgen-inducible TMPRSS2 (Transmembrane protease, serine 2 (21q22.3)) and an ETS (E-twenty six) family transcription factor, ERG (v-ets erythroblastosis virus E26 oncogene like (21q22.2))1.
An apparent intrachromosomal deletion of 3Mb on chromosome 21 fuses TMPRSS2 to ERG. The rearrangement places ERG under the androgen-regulated transcriptional control of TMPRSS22. This fusion is associated with disease progression and the rearrangement in prostate cancer may account for molecular and clinical heterogeneity3. This represents an important subclassification of prostate cancer from a biological and a clinical standpoint3.
It was very important for us to have more consistent results with our probes — easy-to-read bright signals and a range of vial sizes, which is much more cost-effective. It also was critical to upgrade our pretreatment kit to expedite the analysis of FFPE samples. We can now complete the process in about 90 minutes. Janet M. Cowan, PhD, Director of the Cytogenetics Laboratory at Tufts Medical Center
1. Saramaki et al., Clin Cancer Res 2008;14(11):3395-3400
2. Lapointe et al., Modern Pathology 2007;20(4):467-473
3. Perner et al., Cancer Res 2006;66(17):8337-8341
- Area of Interest*
- Prostate Cancer
This product is intended to be used on formalin-fixed paraffin-embedded (FFPE) tissues.
*Disease information supported by the literature and is not a reflection of the intended purpose of this product.